Clinical Scenario
Approximately 86-97% of patients have the TPMT *1/*1 (wild-type) genotype. [1] These patients have normal TPMT enzyme activity. Approximately 3-14% of patients have the heterozygous TPMT genotype and possess one TPMT variant allele. These patients may experience moderate to severe myelosuppression; therefore, thiopurine drug dose reduction may be warranted. [1] [2] The population prevalence of patients who have the homozygous TPMT variant genotype is low (approximately 1 in 178 to 1 in 3,736 patients). [1] However, these patients have the highest risk of developing severe myelosuppression, which may lead to life-threatening complications such as sepsis. [1] [2] [3] These patients may not be candidates for treatment with a thiopurine drug, or the drug dose should be reduced by at least 10-fold. [1] 
Test Description
The TPMT genotype assay uses polymerase chain reaction (PCR) amplication followed by single nucleotide primer extension to detect the TPMT *1, *2, *3A, *3B, and/or *3C alleles. [4] [5] The TPMT genotype assay requires a whole blood sample.
The Clinical Pharmacogenomics Implementation Consortium (CPIC) guidelines: [1] Heterozygous TPMT genotype (intermediate activity) : In patients who possess a single TPMT functional (*1) and nonfunctional allele (*2, *3A, *3B, *3C, or *4), the initial dose of AZA or 6-MP should be reduced by 30-70%. The AZA dose can be titrated as tolerated. The 6-MP dose should be adjusted based on the severity of myelosuppression and disease-specific guidelines. The initial dose of TG should be reduced by 30-50%, and adjusted based on the severity of myelosuppression and disease-specific guidelines.
Homozygous TPMT genotype (variant mutant, low, or deficient activity): Reduce the initial dose of AZA, 6-MP or TG by 10-fold and extend the dosing frequency from daily to three times weekly, or select an alternative drug.
The Royal Dutch Association for the Advancement of Pharmacy Pharmacogenomic Working Group: [18] Patients who are intermediate metabolizers based on the TPMT genotype or phenotype test: The dose of AZA or 6-MP should be reduced by 50% and titrated based on hematologic monitoring and efficacy, or select an alternative drug.
Patients who are poor metabolizers based on the TPMTgenotype or phenotype test: The dose of AZA or 6-MP should be reduced by 90% and titrated based on hematologic monitoring and efficacy, or select an alternative drug.
Patients who are intermediate or poor metabolizers should not be treated with TG as there are "insufficient data to allow calculation of dose adjustment."
Guidelines by professional group
The American College of Gastroenterology treatment guidelines prefer TPMT phenotyping over genotyping because the phenotype assay quantifies the level of TPMT enzyme activity in patients who are being treated with thiopurines for ulcerative colitis (UC). [16] The British Society of Gastroenterology does not require either TPMT genotyping or phenotyping as a prerequisite to initiating thiopurine therapy because the use of AZA has been shown to be safe in patients with Crohn's disease (CD) or UC. [13] [19]
Other groups
The US Food and Drug Administration (FDA) and prescribing information for AZA and 6-MP recommend either TPMT genotyping or phenotyping prior to initiating therapy to help identify patients who are at an increased risk of developing toxicity. [20] [21] [22] The prescribing information for TG indicates that patients with TPMT deficiency "may be unusually sensitive to the myelosuppressive effects of TG. Substantial dosage reductions may be required to avoid the development of lifethreatening bone marrow suppression. Prescribers should be aware that some laboratories offer testing for TPMT deficiency." [17] Despite the risk of myelosuppression and the availability of TPMT tests, the manufacturer does not indicate that testing for TPMT deficiency prior to initiating TG is recommended, or provide dose adjustment guidance based on the TPMT test result.
Evidence Overview

Analytic Validity
A systematic review of published literature was conducted to determine the characteristics of the TPMT tests. [23] The literature evaluated TPMT tests in patients with various ethnicities (e.g., Caucasians, Asians, and African Americans). The patient population analyzed was non-specific; healthy volunteers, those with medical conditions that require thiopurine (e.g., acute lymphoblastic leukemia, IBD), children, and adults were included. The results showed that there are eight different ways in which the TPMT genotype tests can be performed, and no single "gold standard" method for comparison has been accepted. Overall, the TPMT genotype tests had a lower sensitivity and a higher positive predictive value (PPV) in comparison to the TPMTphenotype test. Furthermore, there was a wide range of sensitivity, specificity, PPV and negative predictive value (NPV), which could be due to the variety of genotyping methods. Additionally, these ranges were derived from evaluations of genotype testing methods compared with various reference standards that included both genotyping and enzymatic tests. The Clinical Pharmacogenomics Implementation Consortium (CPIC) guidelines: [1] Heterozygous TPMT genotype (intermediate activity) : In patients who possess a single TPMT functional (*1) and nonfunctional allele (*2, *3A, *3B, *3C, or *4), the initial dose of AZA or 6-MP should be reduced by 30-70%. The AZA dose can be titrated as tolerated. The 6-MP dose should be adjusted based on the severity of myelosuppression and disease-specific guidelines. The initial dose of TG should be reduced by 30-50%, and adjusted based on the severity of myelosuppression and disease-specific guidelines.
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Clinical Validity
Patients with homozygous TPMT (inactive) genotype who are treated with conventional doses of thiopurines have 100% likelihood of developing severe myelosuppression. [1] The odds ratio (OR) of developing leukopenia is 18.60 (95% CI = 4.12-83.60). [2] Approximately 30-60% of patients with heterozygous TPMT genotype experience severe myelosuppression when standard doses of thiopurines are administered. [ Concordance between TPMT genotype and phenotype vary in the published literature. One study showed that approximately 43% of IBD patients who possess one TPMT variant allele had increased TPMT enzyme activity. [30] In another study, the correlation between TPMT phenotype and genotype was 99% amongst patients with IBD who were treated with AZA. [31] 
Clinical Considerations
TPMT genotype status is not the sole reason for increased myelosuppression risk in patients who are treated with thiopurine drugs. Myelosupprression may be the result of drug-drug interactions with agents such as, but not limited to, allopurinol, mesalamine, metronizadole, non-steroidal anti-inflammatory drugs (NSAIDs), and sulfamethoxazole/trimethoprim. [24] Concordance between TPMT genotype and phenotype vary in the published literature. One study showed that approximately 43% of IBD patients who possess one TPMT variant allele had increased TPMT enzyme activity. [30] In another study, the correlation between TPMT phenotype and genotype was 99% amongst patients with IBD who were treated with AZA. [31] 
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